CD38 and plasma cell myeloma: The anti-myeloma activity of daratumumab is mediated by a diverse range of mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, complement-dependent cytotoxicity (CDC), apoptosis and inhibition of the enzymatic effects of CD38 [36].